TABLE 2.

Histopathological characteristics before and after treatment for each therapeutic group

	Treatments
Variables	G		L+G		L+G+BCG
	Before	After	Before	After	Before	After
	n° (%)	n° (%)	n° (%)	n° (%)	n° (%)	n° (%)
Derm
Exudative reactions
Plasmat
light/moderate	3 (37,5)	1 (12,5)	6 (85,7)	1 (14,3)	6 (75,0)	1 (12,5)
Absence	5 (62,5)	7 (87,5)	1 (14,3)	6 (85,7)	2 (25,0)	7 (87,5)
Cellular
Intense	5 (62,5)	0	6 (85,7)	0	6 (75,0)	0
light/moderate	3 (37,5)	8 (100)	1 (14,3)	6 (85,7)	2 (25,0)	8 (100)
Absence	0	0	0	1 (14,3)	0	0
Inflammatory infiltrate
PMNS
< 10%	3 (37,5)	1 (12,5)	4 (57,1)	1 (14,3)	5 (62,5)	1 (12,5)
Absence	5 (62,5)	7 (87,5)	3 (42,9)	6 (85,7)	3 (37,5)	7 (87,5)
Eosinophils
< 10%	2 (25,0)	1 (12,5)	4 (57,1)	1 (14,3)	3 (37.5)	1 (12,5)
Absence	6 (75,0)	7 (87,5)	3 (42,9)	6 (85,7)	5 (62,5)	7 (87,5)
Mononuclear cells
> 10%	6 (75,0)	0	6 (85,7)	0	6 (75,0)	0
< 10%	2 (25,0)	8 (100)	1 (14,3)	6 (85,7)	2 (25,0)	8 (100)
Absence	0	0	0	1 (14,3)	0	0

G: Glucantime; L+G: Leishvacin+Glucantime; L+G+BCG:

Leishvacin+Glucantime+BCG;

PMNS: polymorphonuclear. Analysis frequency.